Analgesic use, parents’ clan, and coffee intake are three independent risk factors of chronic kidney disease in middle and elderly-aged population: a community-based study

References

• United States Renal Data System: 2012 Annual Data Report. The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2012. USRDS 2012. Available at: http://www.usrds.org/atlas.aspx. Accessed August 13, 2013
   Google Scholar
• Xue JL, Ma JZ, Louis TA, Collins AJ. Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J Am Soc Nephrol. 2001;12(12):2753–2758
   PubMedGoogle Scholar
• Wen CP, Cheng TYD, Tsai MK, et al. All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan. Lancet. 2008;371(9631):2173–2182
   PubMed Web of Science ®Google Scholar
• Zeller K, Whittaker E, Sullivan L, et al. Effect of restricting dietary protein on the progression of renal failure in patients with insulin dependent diabetes mellitus. N Engl J Med. 1991;324:78–84
   PubMed Web of Science ®Google Scholar
• Sarnak MJ, Levey AS. Cardiovascular disease and chronic renal disease: a new paradigm. Am J Kidney Dis. 2000;35(4 Suppl. 1):S117–S131
   PubMed Web of Science ®Google Scholar
• Lee PH, Chang HY, Tung CW, et al. Hypertriglyceridemia: an independent risk factor of chronic kidney disease in Taiwanese adults. Am J Med Sci. 2009;338(3):185–189
   PubMedGoogle Scholar
• Chang HY, Tung CW, Lee PH, et al. Hyperuricemia as an independent risk factor of chronic kidney disease in middle-aged and elderly population. Am J Med Sci. 2010;339(6):509–515
   PubMedGoogle Scholar
• Kuo HW, Tsai SS, Tiao MM, Yang CY. Epidemiological features of CKD in Taiwan. Am J Kidney Dis. 2007;49(1):46–55
   PubMedGoogle Scholar
• Yang CS, Lin CH, Chang SH, Hsu HC. Rapidly progressive fibrosing interstitial nephritis associated with Chinese herbal drugs. Am J Kidney Dis. 2000;35(2):313–318
   PubMed Web of Science ®Google Scholar
• Kuo HW, Tsai SS, Tiao MM, et al. Analgesic use and the risk for progression of chronic kidney disease. Pharmacoepidemiol Drug Saf. 2010;19(7):745–751
   PubMedGoogle Scholar
• Jurkovitz C, Franch H, Shoham D, Bellenger J, McClellan W. Family members of patients treated for ESRD have high rates of undetected kidney disease. Am J Kidney Dis. 2002;40:1173–1178
   PubMedGoogle Scholar
• Norris K, Nissenson AR. Race, gender, and socioeconomic disparities in CKD in the United States. J Am Soc Nephrol. 2008;19(7):1261–1270
   PubMed Web of Science ®Google Scholar
• Pham PC, Dewar K, Hashmi S, et al. Pain prevalence in patients with chronic kidney disease. Clin Nephrol. 2010;73(4):294–299
   PubMedGoogle Scholar
• Kuo HW, Tsai SS, Tiao MM, Liu YC, Lee IM, Yang CY. Analgesic use and the risk for progression of chronic kidney disease. Pharmacoepidemiol Drug Saf. 2010;19(7):745–751
   PubMedGoogle Scholar
• Freedman BI, Soucie JM, Kenderes B, et al. Family history of end-stage renal disease does not predict dialytic survival. Am J Kidney Dis. 2001;38:547–552
   PubMedGoogle Scholar
• National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1–S246
   PubMedGoogle Scholar
• Lei CC, Lee PH, Hsu YC, et al. Educational intervention in CKD retards disease progression and reduces medical costs for patients with stage 5 CKD. Ren Fail. 2013;35(1):9–16
   PubMed Web of Science ®Google Scholar
• Gharavi AG, Yan Y, Scolari F, et al. IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6q22–23. Nat Genet. 2000;26:354–357
   PubMed Web of Science ®Google Scholar
• Hanson RL, Craig DW, Millis MP, et al. Identification of PVT1 as a candidate gene for end-stage renal disease in type 2 diabetes using a pooling-based genome-wide single nucleotide polymorphism association study. Diabetes. 2007;56:975–983
   PubMed Web of Science ®Google Scholar
• Födinger M, Veitl M, Skoupy S, et al. Effect of TCN2 776C>G on vitamin B12 cellular availability in end-stage renal disease patients. Kidney Int. 2003;64:1095–1100
   PubMed Web of Science ®Google Scholar
• Wetmore JB, Hung AM, Lovett DH, et al. Interleukin-1 gene cluster polymorphisms predict risk of ESRD. Kidney Int. 2005;68:278–284
   PubMedGoogle Scholar
• Doi K, Noiri E, Nakao A, et al. Functional polymorphisms in the vascular endothelial growth factor gene are associated with development of end-stage renal disease in males. J Am Soc Nephrol. 2006;17:823–830
   PubMed Web of Science ®Google Scholar
• Freedman BI, Soucie JM, Kenderes B, et al. Family history of end-stage renal disease does not predict dialytic survival. Am J Kidney Dis. 2001;38:547–552
   PubMedGoogle Scholar
• Ferguson R, Grim CE, Opgenorth TJ. A familial risk of chronic renal failure among blacks on dialysis? J Clin Epidemiol. 1988;41:1189–1196
   Google Scholar
• Puri TS, Shakaib MI, Chang A. Chronic kidney disease induced in mice by reversible unilateral ureteral obstruction is dependent on genetic background. Am J Physiol Renal Physiol. 2010;298(4):F1024–F1032
   Google Scholar
• Yoshida T, Kato K, Fujimaki T. Association of genetic variants with chronic kidney disease in Japanese individuals. Clin J Am Soc Nephrol. 2009;4:883–890
   PubMedGoogle Scholar
• Datta SK, Kumar V, Pathak R, et al. Association of glutathione S-transferase M1 and T1 gene polymorphism with oxidative stress in diabetic and nondiabetic chronic kidney disease. Ren Fail. 2010;32(10):1189–1195
   PubMed Web of Science ®Google Scholar
• Ma S, Richardson JA, Bitmansour A, et al. Partial depletion of regulatory T cells does not influence the inflammation caused by high dose hemi-body irradiation. PLoS One. 2013;8(2):e56607
   Google Scholar
• Herzlinger S, Horton ES. Extraglycemic effects of glp-1-based therapeutics: addressing metabolic and cardiovascular risks associated with type 2 diabetes. Diabetes Res Clin Pract. 2013;100(1):1–10
   PubMedGoogle Scholar
• Khunti K, Morris DH, Weston CL, et al. Joint prevalence of diabetes, impaired glucose regulation, cardiovascular disease risk and chronic kidney disease in South Asians and White Europeans. PLoS One. 2013;8(1):e55580
   Google Scholar
• Frimodt-Møller M, Kamper AL, Strandgaard S, Kreiner S, Nielsen AH. Beneficial effects on arterial stiffness and pulse-wave reflection of combined enalapril and candesartan in chronic kidney disease–a randomized trial. PLoS One. 2012;7(7):e41757
   Google Scholar
• Song F, Qureshi AA, Han J. Increased caffeine intake is associated with reduced risk of basal cell carcinoma of the skin. Cancer Res. 2012;72(13):3282–3289
   PubMedGoogle Scholar
• Cano-Marquina A, Tarín JJ, Cano A. The impact of coffee on health. Maturitas. 2013;75(1):7–21
   PubMed Web of Science ®Google Scholar
• Freedman ND, Park Y, Abnet CC, Hollenbeck AR, Sinha R. Association of coffee drinking with total and cause-specific mortality. N Engl J Med. 2012;366(20):1891–1904
   PubMed Web of Science ®Google Scholar
• Pham NM, Yoshida D, Morita M, et al. The relation of coffee consumption to serum uric Acid in Japanese men and women aged 49-76 years. J Nutr Metab. 2010; 2010:930757. doi: 10.1155/2010/930757
   PubMedGoogle Scholar